Thoonen, RobrechtSips, PatrickBloch, KennethBuys, Emmanuel2015-03-182012Thoonen, Robrecht, Patrick Y. Sips, Kenneth D. Bloch, and Emmanuel S. Buys. 2012. “Pathophysiology of Hypertension in the Absence of Nitric Oxide/Cyclic GMP Signaling.” Curr Hypertens Rep 15 (1) (December 12): 47–58. doi:10.1007/s11906-012-0320-5.1522-64171534-3111http://nrs.harvard.edu/urn-3:HUL.InstRepos:14229236The nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling system is a well-characterized modulator of cardiovascular function, in general, and blood pressure, in particular. The availability of mice mutant for key enzymes in the NO-cGMP signaling system facilitated the identification of interactions with other blood pressure modifying pathways (e.g. the renin-angiotensin-aldosterone system) and of gender-specific effects of impaired NO-cGMP signaling. In addition, recent genome-wide association studies identified blood pressure-modifying genetic variants in genes that modulate NO and cGMP levels. Together, these findings have advanced our understanding of how NO-cGMP signaling regulates blood pressure. In this review, we will summarize the results obtained in mice with disrupted NO-cGMP signaling and highlight the relevance of this pathway as a potential therapeutic target for the treatment of hypertension.en-USCyclic guanosine monophosphateBlood pressureHypertensionCardiovascular functionSoluble guanylate cyclaseNitric oxideMutant miceGenetic variantsRenin-angiotensin-aldosterone signalingGenderS-nitrosylationTherapeuticsJournal Article2015-03-1810.1007/s11906-012-0320-5